ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Spain Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032
Published Date: 2023-05-01
|
Report Code: ALLI-Auto-1V696
Home | Market Reports
Spain Radiopharmaceuticals Market By Radioisotope Technetium 99m Fluorine 18 Iodine I Gallium 68 Others By Application Cancer Cardiology Others By Type Diagnostic Therapeutic By End User Hospitals and clinics Medical Imaging centers Others Opportunity Analysis and Industry Forecast 2023 2032
BUY CHAPTERS

Spain Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032

Code: ALLI-Auto-1V696
Report
2023-05-01
Pages:77
Allied Market Research
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Induvac
GE Healthcare
Nucleon
Tradeo
INSYSBIO
B-NUCLEAR
NUCLEUS BIOTEK
EGAMMA
PHARMALINE
MEDIPHARMA

Spain Radiopharmaceuticals Market

The rise in cancer, cardiovascular, and neurological illness prevalence, the rise in demand for medical imaging, and the rise in product approval for radiopharmaceuticals are the main factors driving the growth of the Spain radiopharmaceuticals market share. The market is growing as a result of an increase in radiopharmaceutical R&D.
The alarming increase in the prevalence of chronic illnesses, including cancer, cardiovascular diseases, and neurological diseases is a crucial factor propelling the market for radiopharmaceuticals. The demand for radiopharmaceuticals is increased by such disease's rising prevalence as well as the corresponding rise in diagnosis and treatment needs. To identify and treat cancer, radiopharmaceuticals are injected into the body, where they gather in malignant tissues, enabling the detection and management of the illnesses.
Additionally, the market for radiopharmaceuticals is being driven by an increase in PET imaging and a rise in demand for accurate diagnostics. Moreover, during the forecast period, rising physician knowledge of nuclear medicine is anticipated to fuel market expansion for radiopharmaceuticals. The International Atomic Energy Agency had estimated that by 2020, 80% of medical imaging will be used annually to diagnose diseases, including cancer.
Moreover, in March 2023, AtomVie Global Radiopharma Inc., a company in the radiopharmaceutical sector, constructed an industry-leading Contract Development and Manufacturing Organisation (CDMO) facility for radiopharmaceuticals in Ontario, Canada. The brand-new facility will be used exclusively to distribute radiopharmaceuticals medicines around the world. A new subsidiary, Blue Earth Therapeutics, was also launched by Bracco Imaging in March 2022 with the goal of creating the next generation of therapeutic radiopharmaceutical technology. The existence of the radiopharmaceuticals sector offers a chance for the market for radiopharmaceuticals to expand.
On the other hand, side effects of radiopharmaceuticals such as drowsiness, fainting, fever, flushing, headache, nausea, vomiting, stomach pain, skin rashes, and difficulty in breathing are anticipated to limit the growth of the market during the forecast period.
The COVID-19 pandemic has had a significant impact on radiopharmaceuticals market. The pandemic has caused major disruptions to the production and supply of radiopharmaceuticals to the nuclear medicine department, resulting in shortages of radiopharmaceuticals. According to the European Journal of Nuclear Medicine and Molecular Imaging, in July 2021, around 81% of the countries reported a decrease in diagnostic scintigraphy procedures during the COVID-19 pandemic.
INSYSBIO, INDUVAC, B-NUCLEAR, GE HEALTHCARE, NUCLEUS BIOTEK, NUCLEON, TRADEO, EGAMMA, PHARMALINE, MEDIPHARMA are some of the companies operating in the market.

Key Benefits For Stakeholders

●Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
●Analyze the key strategies adopted by major market players in Spain radiopharmaceuticals market.
●Assess and rank the top factors that are expected to affect the growth of Spain radiopharmaceuticals market.
●Top player positioning provides a clear understanding of the present position of market players.
●Detailed analysis of the Spain radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
○ MEDIPHARM

Scope of Spain Radiopharmaceuticals Market Report

Report Metric Details
Report Name Spain Radiopharmaceuticals Market
By Type ● Diagnostic
● Therapeutic
By End User ● Hospitals and clinics
● Medical Imaging centers
● Others
By Radioisotope ● Fluorine 18
● Iodine I
● Gallium 68
● Others
● Technetium 99m
By Application ● Cancer
● Cardiology
● Others
● Key Market Players
○ INSYSBIO
○ INDUVAC
○ B-NUCLEAR
○ GE HEALTHCARE
○ NUCLEUS BIOTEK
○ NUCLEON
○ TRADEO
○ EGAMMA
○ PHARMALINE
● New Product Development/ Product Matrix of Key Players ● Patient/epidemiology data at country, region, global level, ● Regulatory Guidelines, ● Additional company profiles with specific to client's interest, ● Additional country or region analysis- market size and forecast, ● Expanded list for Company Profiles, ● Historic market data, ● Key player details (including location, contact details, supplier/vendor network etc. in excel format), ● SWOT Analysis, Key Market Segments
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

Who are the main players in the Spain Radiopharmaceuticals Market report?

Ans: The main players in the Spain Radiopharmaceuticals Market are ● Patient/epidemiology data at country, region, global level, ● Regulatory Guidelines, ● Additional company profiles with specific to client's interest, ● Additional country or region analysis- market size and forecast, ● Expanded list for Company Profiles, ● Historic market data, ● Key player details (including location, contact details, supplier/vendor network etc. in excel format), ● SWOT Analysis, Key Market Segments

What are the Application segmentation covered in the Spain Radiopharmaceuticals Market report?

Ans: The Applications covered in the Spain Radiopharmaceuticals Market report are ● Cancer, ● Cardiology, ● Others, ● Key Market Players, ○ INSYSBIO, ○ INDUVAC, ○ B-NUCLEAR, ○ GE HEALTHCARE, ○ NUCLEUS BIOTEK, ○ NUCLEON, ○ TRADEO, ○ EGAMMA, ○ PHARMALINE

What are the Type segmentation covered in the Spain Radiopharmaceuticals Market report?

Ans: The Types covered in the Spain Radiopharmaceuticals Market report are ● Diagnostic, ● Therapeutic

What are the End User segmentation covered in the Spain Radiopharmaceuticals Market report?

Ans: The End users covered in the Spain Radiopharmaceuticals Market report are ● Hospitals and clinics, ● Medical Imaging centers, ● Others

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market Size and Forecast, By Radioisotope
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
CHAPTER 5: SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Cancer
5.3. Cardiology
5.4. Others
CHAPTER 6: SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market Size and Forecast, By Type
6.2. Diagnostic
6.3. Therapeutic
CHAPTER 7: SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market Size and Forecast, By End User
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Company 1
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Company 2
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Company 3
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Company 4
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Company 5
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Company 6
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Company 7
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Company 8
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Company 9
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Company 10
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and development
FEATURED COMPANIES
Induvac
GE Healthcare
Nucleon
Tradeo
INSYSBIO
B-NUCLEAR
NUCLEUS BIOTEK
EGAMMA
PHARMALINE
MEDIPHARMA
LIST OF TABLES
TABLE 01. SPAIN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 05. COMPANY 1: KEY EXECUTIVES
TABLE 06. COMPANY 1: COMPANY SNAPSHOT
TABLE 07. COMPANY 1: OPERATING SEGMENTS
TABLE 08. COMPANY 1: PRODUCT PORTFOLIO
TABLE 09. COMPANY 1: KEY STRATERGIES
TABLE 10. COMPANY 2: KEY EXECUTIVES
TABLE 11. COMPANY 2: COMPANY SNAPSHOT
TABLE 12. COMPANY 2: OPERATING SEGMENTS
TABLE 13. COMPANY 2: PRODUCT PORTFOLIO
TABLE 14. COMPANY 2: KEY STRATERGIES
TABLE 15. COMPANY 3: KEY EXECUTIVES
TABLE 16. COMPANY 3: COMPANY SNAPSHOT
TABLE 17. COMPANY 3: OPERATING SEGMENTS
TABLE 18. COMPANY 3: PRODUCT PORTFOLIO
TABLE 19. COMPANY 3: KEY STRATERGIES
TABLE 20. COMPANY 4: KEY EXECUTIVES
TABLE 21. COMPANY 4: COMPANY SNAPSHOT
TABLE 22. COMPANY 4: OPERATING SEGMENTS
TABLE 23. COMPANY 4: PRODUCT PORTFOLIO
TABLE 24. COMPANY 4: KEY STRATERGIES
TABLE 25. COMPANY 5: KEY EXECUTIVES
TABLE 26. COMPANY 5: COMPANY SNAPSHOT
TABLE 27. COMPANY 5: OPERATING SEGMENTS
TABLE 28. COMPANY 5: PRODUCT PORTFOLIO
TABLE 29. COMPANY 5: KEY STRATERGIES
TABLE 30. COMPANY 6: KEY EXECUTIVES
TABLE 31. COMPANY 6: COMPANY SNAPSHOT
TABLE 32. COMPANY 6: OPERATING SEGMENTS
TABLE 33. COMPANY 6: PRODUCT PORTFOLIO
TABLE 34. COMPANY 6: KEY STRATERGIES
TABLE 35. COMPANY 7: KEY EXECUTIVES
TABLE 36. COMPANY 7: COMPANY SNAPSHOT
TABLE 37. COMPANY 7: OPERATING SEGMENTS
TABLE 38. COMPANY 7: PRODUCT PORTFOLIO
TABLE 39. COMPANY 7: KEY STRATERGIES
TABLE 40. COMPANY 8: KEY EXECUTIVES
TABLE 41. COMPANY 8: COMPANY SNAPSHOT
TABLE 42. COMPANY 8: OPERATING SEGMENTS
TABLE 43. COMPANY 8: PRODUCT PORTFOLIO
TABLE 44. COMPANY 8: KEY STRATERGIES
TABLE 45. COMPANY 9: KEY EXECUTIVES
TABLE 46. COMPANY 9: COMPANY SNAPSHOT
TABLE 47. COMPANY 9: OPERATING SEGMENTS
TABLE 48. COMPANY 9: PRODUCT PORTFOLIO
TABLE 49. COMPANY 9: KEY STRATERGIES
TABLE 50. COMPANY 10: KEY EXECUTIVES
TABLE 51. COMPANY 10: COMPANY SNAPSHOT
TABLE 52. COMPANY 10: OPERATING SEGMENTS
TABLE 53. COMPANY 10: PRODUCT PORTFOLIO
TABLE 54. COMPANY 10: KEY STRATERGIES LIST OF FIGURES
FIGURE 01. SPAIN RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF SPAIN RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN SPAIN RADIOPHARMACEUTICALS MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SPAIN RADIOPHARMACEUTICALS MARKET
FIGURE 10. SPAIN RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
FIGURE 11. SPAIN RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. SPAIN RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
FIGURE 13. SPAIN RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 18. COMPETITIVE DASHBOARD
FIGURE 19. COMPETITIVE HEATMAP: SPAIN RADIOPHARMACEUTICALS MARKET
FIGURE 20. TOP PLAYER POSITIONING, 2022
FIGURE 21. COMPANY 1: NET SALES, 2020-2022* ($MILLION)
FIGURE 22. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 23. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 24. COMPANY 2: NET SALES, 2020-2022* ($MILLION)
FIGURE 25. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 26. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 27. COMPANY 3: NET SALES, 2020-2022* ($MILLION)
FIGURE 28. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 29. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 30. COMPANY 4: NET SALES, 2020-2022* ($MILLION)
FIGURE 31. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 32. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 33. COMPANY 5: NET SALES, 2020-2022* ($MILLION)
FIGURE 34. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 35. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 36. COMPANY 6: NET SALES, 2020-2022* ($MILLION)
FIGURE 37. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 38. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 39. COMPANY 7: NET SALES, 2020-2022* ($MILLION)
FIGURE 40. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 41. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 42. COMPANY 8: NET SALES, 2020-2022* ($MILLION)
FIGURE 43. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 44. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 45. COMPANY 9: NET SALES, 2020-2022* ($MILLION)
FIGURE 46. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 47. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 48. COMPANY 10: NET SALES, 2020-2022* ($MILLION)
FIGURE 49. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 50. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%
SELECT A FORMAT
Added to Cart
Electronic

$3570

Single User License
Electronic

$4560

Multi User License
Electronic

$5550

Enterprise License
Electronic

$2670

Data Pack License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions